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IL-2, a lymphokine secreted by T cellsthat functions in the growth and differenti-
ation of lymphocytes and monocytes, binds to a 55-kD glycoprotein (p55), desig-
nated CD25, with low affinity (N10-40 nM kD) and a 70-75 kD glycoprotein (p75)
with an intermediate affinity (-1-5 nM kD) (1-4). The high affinity IL-2 receptor
(-10-30 pM kD) is composed of noncovalently associated p55 and p75 subunits
(1-4). Several laboratories have generated mAbs against the p55 and p75 IL-2 binding
proteins (5, 6), thus allowing for the detection of these receptors on leukocyte popu-
lations.
NK cells are a distinct population of CD3e -,CD56+ lymphocytes that do not rear-
range or express TCR genes and are characterized by their ability to mediate MHC-
unrestricted cytotoxicity against a variety of tumor- and virus-infected cell lines (7).
IL-2 directly activates NK cells, resulting in proliferation and the induction of cyto-
toxic activity (8-10). The majority of peripheral blood CD16+ NK cells constitu-
tively express the p75 IL-2R, and mAbs against p75 IL-2R efficiently block IL-2-
dependent functions, suggestingthat the p75 IL-2Ris the predominant IL-2 binding
structure on resting NK cells (11). We have previously reported that two subsets of
NK cells can be identified based on expression of CD16 (FcR-yIII). Whereas most
peripheral blood NK cells express the phenotype CD16+,CD56+ , a minor subset of
NK cells are CD16- ,CD56+ (referred to as CD16 - NK cells) (12, 13). Neither of
these subsets expresses CD3e or rearranges TCR genes, but both mediate NK cyto-
toxic function and express many similar phenotypic characteristics (12, 13). In the
present study, we demonstrate that CD16- NK cells constitutively express high
affinity IL-2 receptors in vivo and preferentially respond to low amounts of IL-2 .
Materials and Methods
Cell Purification andCulture.
￿
PBMC were isolated by Ficoll/Hypaque centrifugation. After
plastic adherence and passage through nylon wool, NK cells were enriched by centrifugation
on discontinuous gradients ofPercoll (Pharmacia Fine Chemicals, Piscataway, NJ) (10). Cells
were cultured in RPMI 1640 media (M. A. Bioproducts, Walkersville, MD) supplemented
with 4% horse serum (KC Biologicals, Lenexa, KS), 1 MM L-glutamine (Gibco Laborato-
ries, Grand Island, NY), and antibiotics. rIL-2 (18 x 106 IU/mg) was generously provided
by CetusCorp., Emeryville, CA. For proliferation assays, cells were incubated in 96-well cul-
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ture plates and harvested after 4 d following an overnight pulse with (3H]thymidine (1
pCi/well; Amersham Corp., Arlington Heights, IL).
Monoclonal Antibodies.
￿
TU27 mAb (generously provided by Dr. K. Sugamura, Tohoku
University School ofMedicine, Sendai, Japan) reacts with the p75 IL-2R and inhibits binding
of IL-2 to this receptor (5). Leu series mAbs and anti-CD25 (clone 2A3) were produced by
Becton Dickinson Monoclonal Center, Inc. (Mountain View, CA). Phycoerythrin (PE)-
conjugated TU27 and anti-CD25 mAbs were generously provided by Dr. A. Jackson and
Mr. A. Blidy, Becton Dickinson Monoclonal Center.
Immunofluorescence and Flow Cytometry.
￿
Immunofluorescence and flow cytometry were per-
formed as previously described (10) . Cells were analyzed on a FACScan, and cell sorting was
performed on a FACStar or FAGS IV (Becton Dickinson Immunocytometry Systems, San
Jose, CA).
Cytotoxicity Assay.
￿
Cell-mediated cytotoxicity was measured in a 4-h "Cr-release assay (10).
IL-2 Binding Assay.
￿
IL-2 binding assays and Scatchard analysis were performed as previ-
ously described (14). All reagents for the binding assays were generously provided by Dr.
Kendall Smith (Dartmouth Medical School, Hanover, NH).
Results and Discussion
Expression ofp75 and p55 IL-2 Receptors on CD16- and CD16' NK Cells.
￿
PBL en-
riched for NK cells using Percoll density gradients were stained with FITC anti-
CD56 and PE anti-CD25 or PE anti-p75 IL-2R and analyzed by two-color im-
munofluorescence. As previously reported (12), the majority of circulating resting
NK cells express low surface density CD56 and high surface density CD16 (CD16+
CD56d'°" NK cells). A small subset of NK cells do not express CD16, but have
significantly higher surface density CD56 (CD16-CD56b"ght' NK cells). Neither of
these NK cell subsets express CD3 (12). Based on analysis of more than 20 normal
donors, both CD16- CD56br'gh' and CD16+CD56d""+ NK cell subsets expressed the
p75 IL-2R; however, only the CD16-CD56br'ghc+ NK cells constitutively expressed
detectable CD25 (Fig. 1). The finding that the major subset of NK cells (CD16+-
CD56d'm+) express only the p75 IL-2R and mediate IL-2-dependent functions pri-
marily through an intermediate affinity receptor is consistent with prior reports (1-4,
11). Co-expression of CD25 and p75 IL-2R on the CD16-CD56b°gh'+ NK cells sug-
gested that these cells possess high affinity IL-2 receptors.
Differential response of CD16- and CD16' NK Cells to Low Concentrations of rIL-2.
CD16- and CD16' NK cells were isolated to >98% purity by cell sorting, incubated
with various concentrations of rIL-2, and assayed for cytolytic activation and IL-2-
dependent proliferation (Fig. 2). Consistent with the presence of high affinity IL-2
receptors, CD16 - NK cells showed a significantly greater magnitude of IL-2-
induced cytolytic activation and proliferation than CD16' NK cells. CD16- NK cells
demonstrated potent cytolytic activation and proliferation at IL-2 concentrations
as low as 9 IU/ml. CD16' NK cells required significantly higher concentrations of
IL-2, consistent with intermediate affinity IL-2 receptors being the primary IL-2
signal-transducing structure on these cells.
IL-2 BindingAssays.
￿
IL-2 binding assays were performed to determine the number
and affinity of the IL-2 receptors. Scatchard analysis demonstrated the presence of
-1,200 high affinity (-25 pM kD) and -9,600 intermediate affinity (-2 nM kD)
IL-2 receptors on CD16" NK cells (Fig. 3). CD16' NK cells expressed only a single
intermediate affinity IL-2 receptor of -1.9 nM kD (-9,000 sites per cell). The IL-2
binding data thus substantiated the phenotypic and functional studies and defini-NAGLER ET AL.
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FIGURE 1 .
￿
Expression ofIL-2 receptors on NK cell subsets .
PBL enriched for NK cells were stained with FITC-con-
jugated IgM control mAbs and PE-conjugated IgGi con-
trolmAb (A) or FITC-conjugated anti-CD56 (clone L185)
and PE-conjugated anti-p75 IL-2R (TU27 ; B) or FITC-
conjugated anti-CD56andPE-conjugated anti-CD25 (clone
2A3; C). Flowcytometric data are presented as contour plots
(xandy axes are4-decade logscales). Markers defining quad-
rants were positioned to include >98% of unstained cells
in lower left quadrant .
tively showed that the differential responsiveness ofCD16- and CD16' NK cells to
IL-2 is manifested through different affinity IL-2 receptors .
Effects of Anti-IL-2 Receptor mAbs on IL-2-dependent Functions.
￿
Experiments were
undertaken to determine the effects ofblocking mAbs against p75 IL-2R andCD25
on IL-2-dependent functions of CD16 - and CD16+ NK cell subsets . As previously
reported (11), mAbs against p75 IL-2R effectively blocked IL-2 activation ofCD16+
NK cells (Fig. 4, A, B) . Interestingly, although anti-CD25mAbalone failed to affect
IL-2-induced activation (as would be expected from the phenotypic and binding
studies), anti-CD25 mAb slightly increased the inhibition observed with anti-p75
IL-2RmAb(Fig . 4, A, B) . These resultssuggest that functional high affinity receptors
may be present in very low levels (undetectable by IL-2 binding assays or flow cytom-1530
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FIGURE 2 .
￿
Effects of IL-2 concentration on
activation andproliferation ofNK cell subsets .
CD16'CD56d- (/) and CD16-CD566r'gh,
(®) NK cells were sorted to >98% purity, in-
cubated with various concentrations of IL-2
(IU/ml x 10- ') overnight, and assayed for
cytotoxicity against the NK cell-resistant
tumor cell line Colo-205 at an E/T ratio of
25 :1 (A) . Resting NK cell subsets do not lyse
Colo-205 (10) . For proliferation assays (B, C),
cells were plated at 5 x 106 cells/ml (B) or
5 x 10 4 cells/ml (C in the presence of var-
ious concentrations of IL-2 . Proliferation was
assessed by ['Hlthymidine incorporation
after 4 d in culture .
etry) on these cells and that neutralization requires the presence of both anti-p75
IL-2R and anti-CD25 mAb.
IL-2-induced cytolytic activation of CD16- NK cells was inhibited by the anti-
p75 IL-2R mAb, but not by anti-CD25 mAb (Fig . 4 A) . A combination of both
anti-p75 IL-2R and anti-CD25 mAbs was more effective than anti-p75 IL-2RmAb
alone in inhibiting cytolytic activation . Surprisingly, neither anti-p75 IL-2R nor anti-
CD25 mAb alone affected IL-2-dependent proliferation ofCD16-NK cells, whereas
acombination ofbothmAb gave pronounced inhibition (Fig . 4 C) . Previous studies
have shown that thesemAbs against CD25 and p75 IL-2R are effective in inhibiting
binding of IL-2 to the high affinity receptor (5). SinceCD16- NK cells express high
affinity IL-2 receptors presumably consisting of a p75/p55 complex, it was surprising
that high concentrations (20-30 ug/ml) ofthese mAbs individually had no significant
effect on IL-2-induced proliferation . Similar results have recently been reported for
mAb blocking of IL-2-dependent proliferation ofT cell lines expressing both inter-
mediate and high affinity IL-2 receptors (5, 6) . Relative affinityandbinding kinetics
of the mAb versus ligand may account for these results.a
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A. CD16-Negative NK cells.
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B. CD16-positive NK cells
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FIGURE 3.
￿
Binding of 1 1251JIL-2 to NK cell subsets. Peripheral blood CD16- (A) and CD16`
(B) NK cells, isolated to >98% purity, were incubated with serial various concentrations of 1211-
labeled IL-2 for 45 min at 37°C (2 x 105 cells/determination) and then centrifuged through a
cushion of oil to separate bound from unbound IL-2 (14). Nonspecific binding was determined
in the presence of 200 molar excess of unlabeled IL-2. Data are represented as Scatchard plots.
Recently, it has been shown that a substantial proportion of peripheral blood
CD4 + T lymphocytes express low levels of CD25 (15); however, these T cells usu-
ally express only low affinity IL-2 receptors, lack p75 IL-2R, and are unresponsive
to IL-2 (5, 6, 11, and Phillips, J. H., unpublished observation). Therefore, the
CD16- NK cell subset represents the only consistently detectable population of lym-
phocytes in peripheral blood ofnormal adults that constitutively expresses high affinity
IL-2 receptors in vivo. Based on an extensive study of these cells, we have suggested
that CD16 - NK cells may represent a peripheral blood progenitor population for
mature CD16+ NK cells (13) . If this is the case, the presence of high affinity IL-2
receptors may allow expansion and differentiation of these cells with physiological
concentrations of IL-2. Alternatively, CD16 - NK cells may represent a distinct NK
subset that constitutively expresses high affinity IL-2 receptors as a consequence of
activation in vivo. Nonetheless, the presence of high affinity IL-2 receptors would
permit preferential responsiveness of CD16- NK cells in patients treated with rIL-2
for therapeutic purposes . Recent studies have shown a pronounced expansion of the
CD16- NK cell subset in the peripheral blood of cancer patients after in vivo rIL-2
therapy (16, 17) . During normal immune responses, CD16- NK cells may respond
to IL-2 produced in vivo by T cells after antigenic stimulation. CD16- NK cells
have been shownto transcribe TNF-a and granulocyte/macrophage CSF (GM-CSF)
after activation with IL-2 in vitro (13). If this occurs in vivo, these cells may be an
important source of cytokine production in physiological situations.
Summary
The majority of human NK cells express low affinity IgG Fc receptors (CD16+),
whereas a minor subset of NK cells lack Fc receptor expression (CD16-). In con-
trast to CD16 + NK cells that express only p75 IL-2 receptors, CD16- NK cells con-
stitutively co-express both p75 and p55 IL-2 receptors in vivo and preferentially
respond to low concentrations ofIL-2 with increased cytolytic activation and prolifer-1532
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FIGURE 4 .
￿
Effects of anti-IL-2R mAbs on
IL-2-induced cytotoxicity and proliferation .
CD16' (/) and CD16 - (®) NK cell subsets
were isolated to >98% purity by cell sorting
and incubated with # IU/rnl rIL-2 in the pres-
ence or absence ofcontrol (Co)or neutralizing
anti-p75 and/or p55 (CD25) IL-2R mAb
(30 Wg/ml), as indicated . Cells were harvested
after overnight culture for cytotoxicity assays
(target # Colo-205 ; E/T ratio, 25:1) . Prolifer-
ation was assessed by [ ;H]thymidine incor-
poration after 4 d in culture .
ation . Scatchard analysis demonstrated the presence of -1,200 high affinity (-25
pM kD) and -9,600 intermediate affinity (-2 nM kD) IL-2 receptors on CD16-
NK cells . CD16' NK cells expressed only a single intermediate affinity IL-2
receptor of -1 .9 nM kD (-9,000 sites per cell) . The IL-2 binding data thus sub-
stantiated thephenotypic and functional studiesanddefinitively show that the differen-
tial responsiveness of CD16 - and CD16' NK cells to IL-2 is manifested through
different affinity IL-2 receptors .NAGLER ET AL.
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